Other equities research analysts also recently issued reports about the stock. Canaccord Genuity boosted their price target on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the company a buy rating in a research note on Wednesday, February 21st. Zacks Investment Research raised shares of Halozyme Therapeutics from a hold rating to a buy rating and set a $22.00 price target on the stock in a research note on Tuesday, December 12th. BidaskClub raised shares of Halozyme Therapeutics from a hold rating to a buy rating in a research note on Tuesday, December 12th. Deutsche Bank set a $21.00 price target on shares of Halozyme Therapeutics and gave the company a buy rating in a research note on Wednesday, January 24th. Finally, Barclays cut shares of Halozyme Therapeutics from an overweight rating to a hold rating and lifted their price objective for the company from $16.00 to $19.00 in a report on Wednesday, November 22nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the company. Halozyme Therapeutics presently has an average rating of Hold and an average target price of $19.89.
Shares of Halozyme Therapeutics stock opened at $20.82 on Friday. The stock has a market cap of $2,950.24, a P/E ratio of 54.79 and a beta of 1.87. Halozyme Therapeutics has a 52 week low of $11.41 and a 52 week high of $21.36. The company has a quick ratio of 3.85, a current ratio of 3.89 and a debt-to-equity ratio of 0.60.
Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.27. The business had revenue of $189.60 million for the quarter, compared to the consensus estimate of $173.11 million. Halozyme Therapeutics had a net margin of 19.89% and a return on equity of 89.83%. The business’s revenue was up 386.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.21) EPS. sell-side analysts anticipate that Halozyme Therapeutics will post -0.82 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in HALO. Lido Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $202,000. 361 Capital LLC acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $207,000. Raymond James & Associates acquired a new position in shares of Halozyme Therapeutics in the fourth quarter valued at approximately $216,000. Trexquant Investment LP acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $224,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $227,000. Hedge funds and other institutional investors own 85.64% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Halozyme Therapeutics (HALO) Lifted to “B-” at TheStreet” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/03/20/halozyme-therapeutics-halo-lifted-to-b-at-thestreet.html.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.